Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD ...

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

Mantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatment appears to be successful, the cancer often returns and is difficult to cure. A new therapy ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and ...

The ECHO trial's international scope, spanning 27 countries, underscores the global effort to improve treatment for this aggressive form of non-Hodgkin lymphoma.

Calquence ® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma. News release. AstraZeneca. October 3, 2024.

Mantle cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma arising from malignant B cells in the mantle zone of lymph nodes. It accounts for about 5% of lymphoma cases, is more common ...